C
CTKB icon

Covestor’s Cytek Biosciences CTKB Stock Holding History

Covestor’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Hold
21
– – ﹤0.01% 2334
2025
Q4 		$0 Hold
21
– – ﹤0.01% 2327
2025
Q3 		$0 Hold
21
– – ﹤0.01% 2349
2025
Q2 		$0 Buy
21
+11
+110% +$37 ﹤0.01% 2285
2025
Q1 		$0 Hold
10
– – ﹤0.01% 2300
2024
Q4 		$0 Sell
10
-15
-60% -$89 ﹤0.01% 2306
2024
Q3 		$0 Buy
25
+15
+150% +$85 ﹤0.01% 2292
2024
Q2 		$0 Hold
10
– – ﹤0.01% 2306
2024
Q1 		$0 Sell
10
-22
-69% -$174 ﹤0.01% 2306
2023
Q4 		$0 Buy
32
+20
+167% +$126 ﹤0.01% 2216
2023
Q3 		$0 Sell
12
-21
-64% -$168 ﹤0.01% 2193
2023
Q2 		$0 Buy
33
+19
+136% +$170 ﹤0.01% 2205
2023
Q1 		$0 Hold
14
– – ﹤0.01% 2101
2022
Q4 		$0 Sell
14
-1
-7% -$13 ﹤0.01% 2135
2022
Q3 		$0 Sell
15
-3
-17% -$39 ﹤0.01% 2076
2022
Q2 		$0 Sell
18
-6
-25% -$60 ﹤0.01% 1985
2022
Q1 		$0 Buy
+24
New +$324 ﹤0.01% 2159

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Covestor's CTKB Position: Q1 2026 in Review

Covestor held its Cytek Biosciences (CTKB) position steady in Q1 2026 at 21 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2334.

Covestor first reported a position in CTKB in Q1 2022 and has held it in 17 quarters since. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • Covestor held 21 shares of Cytek Biosciences worth $0 as of Q1 2026.
  • Covestor left its Cytek Biosciences share count unchanged in Q1 2026.
  • Cytek Biosciences made up ﹤0.01% of Covestor's portfolio in Q1 2026, its #2334 holding.
  • Covestor first reported a position in Cytek Biosciences in Q1 2022 and has held it in 17 quarters since.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Covestor's 13F filing for Q1 2026, filed 5 May 2026.